FAP and neoplasm: Brünker et al. designed and engineered a bispecific FAP-DR5 antibody that simultaneously targeted the FAP protein in CAFs and the death receptor 5 (DR5) in tumor cells, thereby providing an extrinsic apoptotic pathway that was targeted towards DR5 clustering and capable of specifically activating tumor cells [82].